MESOBLAST LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.075 AUD | -0.92% |
|
+2.87% | +246.77% |
Presentation Operator MessageOperator (Operator)Thank you all for standing by. Hello, and welc...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Companyâs Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Companyâs licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
Calendar
28/05/2024
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.085
AUD
Average target price
1.1
AUD
Spread / Average Target
+1.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +246.77% | 828M | |
| +33.63% | 50.93B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- Transcript : Mesoblast Limited, Q3 2023 Earnings Call, May 26, 2023
